Fig. 1

The 5-year survival rate. The mean survival period was 75.2 months (60–90), and 25 patients were alive and tumor-free, of which 16 osteosarcoma, 6 chondrosarcoma, 2 giant cell tumor of bone, and 1 mucus chondrosarcoma. Thus, the 5-year survival rate was 43.1 %. Sixteen patients died of lung metastasis, of which nine patients had local recurrence and lung metastasis (two patients received postoperative amputation and resection of lung metastatic foci). Eleven patients died of complications including infection, cachexia, and renal failure. Four patients died of other diseases and two patients died of reaction of chemotherapy